Avalo Therapeutics Inc Financials
This page shows Avalo Therapeutics Inc (AVTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash runway, not reported revenue, dominates here as R&D spending and investing uses outran recent financing support.
FY2025 turned a well-funded balance sheet into a much tighter cash position: cash fell from$134.5M in FY2024 to$15.9M . The depletion was not just the accounting loss; operating cash use of$51.5M plus investing outflow of$81.7M shows the company was funding research and asset deployment at the same time.
This is functioning like a development-stage biotech, not a scaled commercial business: FY2025 revenue was only
The capital structure is still equity-funded rather than debt-driven, with liabilities of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Avalo Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Avalo Therapeutics Inc has an operating margin of -123601.7%, meaning the company retains $-123602 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -15535.6% the prior year.
Avalo Therapeutics Inc's revenue declined 86.6% year-over-year, from $441K to $59K. This contraction results in a growth score of 0/100.
Avalo Therapeutics Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.14, Avalo Therapeutics Inc holds $8.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Avalo Therapeutics Inc generates a -94.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -26.4% the prior year.
Avalo Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Avalo Therapeutics Inc generates $0.66 in operating cash flow (-$51.5M OCF vs -$78.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Avalo Therapeutics Inc generated $59K in revenue in fiscal year 2025. This represents a decrease of 86.6% from the prior year.
Avalo Therapeutics Inc's EBITDA was -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.2% from the prior year.
Avalo Therapeutics Inc reported -$78.3M in net income in fiscal year 2025. This represents a decrease of 122.8% from the prior year.
Avalo Therapeutics Inc earned $-5.84 per diluted share (EPS) in fiscal year 2025. This represents an increase of 72.1% from the prior year.
Cash & Balance Sheet
Avalo Therapeutics Inc held $15.9M in cash against $0 in long-term debt as of fiscal year 2025.
Avalo Therapeutics Inc had 19M shares outstanding in fiscal year 2025. This represents an increase of 76.8% from the prior year.
Margins & Returns
Avalo Therapeutics Inc's operating margin was -123601.7% in fiscal year 2025, reflecting core business profitability. This is down 108066.1 percentage points from the prior year.
Avalo Therapeutics Inc's net profit margin was -132642.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 124676.6 percentage points from the prior year.
Avalo Therapeutics Inc's ROE was -94.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 67.8 percentage points from the prior year.
Capital Allocation
Avalo Therapeutics Inc invested $50.1M in research and development in fiscal year 2025. This represents an increase of 105.0% from the prior year.
AVTX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | N/A | N/A | N/A | $249K | $0 | $0 |
| Cost of Revenue | N/A | N/A | $0 | N/A | N/A | -$714K-308.2% | $343K+528.8% | -$80K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | -$343K | N/A |
| R&D Expenses | N/A | $13.6M-3.2% | $14.1M+54.3% | $9.1M | N/A | $9.5M+107.3% | $4.6M+117.4% | $2.1M |
| SG&A Expenses | N/A | $5.6M+6.4% | $5.2M-5.5% | $5.5M | N/A | $4.3M-5.3% | $4.5M+41.8% | $3.2M |
| Operating Income | N/A | -$19.2M+0.6% | -$19.3M-31.7% | -$14.7M | N/A | -$12.9M-34.3% | -$9.6M+70.8% | -$32.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $11K-31.3% | $16K+100.0% | $8K | N/A | -$14K-300.0% | $7K0.0% | $7K |
| Net Income | N/A | -$30.6M-47.5% | -$20.8M-57.9% | -$13.1M | N/A | $23.0M-76.6% | $98.5M+181.2% | -$121.3M |
| EPS (Diluted) | N/A | $-2.19-14.1% | $-1.92-53.6% | $-1.25 | N/A | $-2.83 | $-14.07+90.0% | $-141.14 |
AVTX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $116.5M-6.9% | $125.1M-1.2% | $126.6M-8.6% | $138.5M-8.1% | $150.7M+53.1% | $98.5M-9.1% | $108.3M-12.5% | $123.7M |
| Current Assets | $105.3M-7.5% | $113.8M-1.2% | $115.2M-9.3% | $126.9M-8.6% | $138.9M+61.2% | $86.1M-10.2% | $95.9M-13.8% | $111.2M |
| Cash & Equivalents | $15.9M-41.2% | $27.0M-36.2% | $42.3M-66.2% | $125.0M-7.1% | $134.5M+64.4% | $81.9M-12.4% | $93.4M-15.2% | $110.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M |
| Total Liabilities | $33.4M-0.4% | $33.6M+52.5% | $22.0M+38.4% | $15.9M-10.1% | $17.7M-76.6% | $75.7M-31.4% | $110.5M-50.9% | $224.8M |
| Current Liabilities | $12.9M+62.3% | $8.0M-13.9% | $9.3M+64.9% | $5.6M-19.3% | $7.0M-88.5% | $60.7M-37.1% | $96.4M-55.3% | $215.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $83.0M-9.3% | $91.5M-12.5% | $104.6M-14.7% | $122.6M-7.8% | $133.0M+531.2% | $21.1M+254.9% | -$13.6M+87.9% | -$112.5M |
| Retained Earnings | -$448.5M-3.2% | -$434.8M-7.6% | -$404.2M-5.4% | -$383.4M-3.6% | -$370.3M-10.6% | -$334.9M+6.4% | -$358.0M+21.6% | -$456.4M |
AVTX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.2M+12.9% | -$16.4M-43.7% | -$11.4M-20.4% | -$9.5M+37.1% | -$15.0M-30.5% | -$11.5M+29.2% | -$16.3M-162.5% | -$6.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $2.4M+118.1% | -$13.3M+81.3% | -$70.9M | $0 | $0 | $0 | $0-100.0% | $356K |
| Financing Cash Flow | $687K-95.2% | $14.4M+3163.8% | -$469K | $0-100.0% | $67.7M | $0+100.0% | -$472K-100.4% | $108.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AVTX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -5165.1% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 9251.8% | N/A | N/A |
| Return on Equity | N/A | -33.5%-13.6pp | -19.9%-9.1pp | -10.7% | N/A | 109.3% | N/A | N/A |
| Return on Assets | N/A | -24.5%-8.1pp | -16.4%-6.9pp | -9.5% | N/A | 23.4%-67.5pp | 90.9%+188.9pp | -98.0% |
| Current Ratio | 8.14-6.1 | 14.28+1.8 | 12.44-10.2 | 22.61+2.7 | 19.96+18.5 | 1.42+0.4 | 0.99+0.5 | 0.52 |
| Debt-to-Equity | 0.40+0.0 | 0.37+0.2 | 0.21+0.1 | 0.130.0 | 0.13-3.5 | 3.59+11.7 | -8.12-6.1 | -2.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Avalo Therapeutics Inc's annual revenue?
Avalo Therapeutics Inc (AVTX) reported $59K in total revenue for fiscal year 2025. This represents a -86.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Avalo Therapeutics Inc's revenue growing?
Avalo Therapeutics Inc (AVTX) revenue declined by 86.6% year-over-year, from $441K to $59K in fiscal year 2025.
Is Avalo Therapeutics Inc profitable?
No, Avalo Therapeutics Inc (AVTX) reported a net income of -$78.3M in fiscal year 2025, with a net profit margin of -132642.4%.
What is Avalo Therapeutics Inc's EBITDA?
Avalo Therapeutics Inc (AVTX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Avalo Therapeutics Inc's operating margin?
Avalo Therapeutics Inc (AVTX) had an operating margin of -123601.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Avalo Therapeutics Inc's net profit margin?
Avalo Therapeutics Inc (AVTX) had a net profit margin of -132642.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Avalo Therapeutics Inc's return on equity (ROE)?
Avalo Therapeutics Inc (AVTX) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Avalo Therapeutics Inc's operating cash flow?
Avalo Therapeutics Inc (AVTX) generated -$51.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Avalo Therapeutics Inc's total assets?
Avalo Therapeutics Inc (AVTX) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Avalo Therapeutics Inc spend on research and development?
Avalo Therapeutics Inc (AVTX) invested $50.1M in research and development during fiscal year 2025.
What is Avalo Therapeutics Inc's current ratio?
Avalo Therapeutics Inc (AVTX) had a current ratio of 8.14 as of fiscal year 2025, which is generally considered healthy.
What is Avalo Therapeutics Inc's debt-to-equity ratio?
Avalo Therapeutics Inc (AVTX) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Avalo Therapeutics Inc's return on assets (ROA)?
Avalo Therapeutics Inc (AVTX) had a return on assets of -67.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Avalo Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Avalo Therapeutics Inc (AVTX) had $15.9M in cash against an annual operating cash burn of $51.5M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Avalo Therapeutics Inc's Piotroski F-Score?
Avalo Therapeutics Inc (AVTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Avalo Therapeutics Inc's earnings high quality?
Avalo Therapeutics Inc (AVTX) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Avalo Therapeutics Inc?
Avalo Therapeutics Inc (AVTX) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.